AMENDMENTS TO THE CLAIMS

1. (Currently Amended) N''-Substituted 9a-N- (N'-carbamoyl-γ-aminopropyl), 9a-N-(N'-thiocarbamoyl-γ-aminopropyl), 9a-N-[N'-(β-cyanoethyl)-N'-carbamoyl-γ-aminoprolpyl] and- 9a-N- [N'-((β-cyanoethyl)-N'-thiocarbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9- -deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series of the general formula 1,



wherein R represents H or cladinosyl moiety,

R^1 represents H or β-cyanoethyl moiety,

R^2 represents isopropyl, 1-naphtyl, 2-naphtyl, benzyl, 2-(trifluoromethyl)phenyl, 3-phenylpropyl, β-phenylethyl, ethoxycarbonyl-methyl, 1-(1-naphtyl)ethyl, 3,4,5-trimethoxyphenyl ~~and~~ or a 2,4-dichlorophenyl group, and

X represents O ~~and~~ or S,

and their acceptable addition salts thereof with inorganic or organic acids.

2. (Currently Amended) Substance according to claim1, characterized in that ~~R represents cladinosyl group and~~ R^1 represents H, R^2 represents isopropyl group and X is O.

3. (Currently Amended) Substance according to claim1, characterized in that ~~R represents cladinosyl group~~, R^1 represents H, and R^2 represents 1-naphthyl group and X is O.

4. (Currently Amended) Substance according to claim1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents 2-naphtyl group and X is O.

5. (Currently Amended) Substance according to claim 1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents benzyl group and X is O.

6. (Currently Amended) Substance according to claim 1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents 2-(trifluoromethyl) phenyl group and X represents O.

7. (Currently Amended) Substance according to claim1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents 3-phenylpropyl group and X is S.

8. (Currently Amended) Substance according to claim1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents β-phenylethyl group and X is S.

9. (Currently Amended) Substance according to claim 1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents ~~etoxycarbonylmethyl~~ ethoxycarbonylmethyl group and X is O.

10. (Currently Amended) Substance according to claim1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents l-(l-naphtyl) ethyl group and X is O.

11. (Currently Amended) Substance according to claim 1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents 3,4, 5-trimethoxyphenyl group and X is O.

12. (Currently Amended) Substance according to claim 1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents 2,4-dichlorophenyl group and X is O.

13. (Currently Amended) Substance according to claim 1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents H and R^2 represents benzyl group or 1-naphtyl group and X is S.

Claims 14 – 19 (Canceled)

20. (Currently Amended) Substance according to claim 1, characterized in that ~~R represents cladinosyl group~~, R^1 represents β-cyanoethyl group, R^2 represents 3-phenylpropyl group and X is S.

21. (Currently Amended) Substance according to claim 1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents β-cyanoethyl group, R^2 represents β-phenylethyl group and X is S.

Claims 22 - 24 (Canceled)

25. (Currently Amended) Substance according to claim 1, characterized in that ~~R represents cladinosyl group,~~ R^1 represents β-cyanoethyl group, R^2 represents 2,4-dichlorophenyl group and X is O.

Claims 26 – 53 (Canceled)

54. (Currently Amended) Process for the preparation of N''-substituted 9a-N- (N'-carbamoyl-γ-aminopropyl), 9a-N-(N'-thiocarbamoyl-γ-aminopropyl), 9a-N-[N'-(β-cyanoethyl)-N'-carbamoyl-γ-aminopropyl] and 9a-N- [N'- (β-cyanoethyl)-N'-thiocarbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, of the general formula 1,



1

wherein R represents H or cladinosyl moiety,

R^1 represents H or β-cyanoethyl moiety,

R^2 represents isopropyl,1-naphtyl, 2-naphtyl, benzyl, 2-(trifluoromethyl) phenyl, 3-phenylpropyl, β-phenylethyl, ethoxycarbonylmethyl, l-(l-naphtyl)ethyl, 3,4, 5-trimethoxyphenyl and 2,4-dichlorophenyl group, and

X represents O ~~and~~ or S,

characterized in that 9a-N- (γ-aminopropyl) and 9a-N-[N'-(β-cyanoethyl)-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A general formula 2,



2

wherein R represents H ~~and~~ or a cladinosyl group and

R^1 represents H ~~and~~ or a β-cyanoethyl group

is reacted with isocyanates or isothiocyanates general formula 3

~~$R^2—N=C=O$ 3~~

$R^2—N=C=X$ 3

wherein R^2 represents isopropyl,1-naphtyl, 2-naphtyl, benzyl, 2- (trifluoromethyl) phenyl, 3-phenylpropyl,(3-phenylethyl, ethoxycarbonyl- methyl, 1-(1-naphtyl) ethyl, 3,4, 5-trimethoxyphenyl and 2,4-dichlorophenyl group, and

X represents O ~~and~~ or S,

in toluene, xylene or some others aprotic solvents at a temperature 0° -110° C and then, if appropriate, to a reaction with inorganic or organic acids.

55. (Currently Amended) Pharmaceutical compositions comprising a pharmaceutically acceptable ~~carier~~ carrier and an antibacterially effective amount of the ~~subsatnces~~ substance according to claim 1.

56. (Canceled)

57. (New) A method of treating bacterial infections comprising administering the substance according to claim 1.

58. (New) The method according to claim 57, wherein R^1 represents H.

59. (New) The method according to claim 57, wherein R^2 represents a 1-naphthyl, 2-naphthyl, 1-(1-naphtyl)ethyl, or 2,4-dichlorophenyl group.